EPISODE · Oct 18, 2022 · 33 MIN
Why Clinical Trial Enrollment Sucks
from Out of Patients with Matthew Zachary
My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
What this episode covers
My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
NOW PLAYING
Why Clinical Trial Enrollment Sucks
No transcript for this episode yet
Similar Episodes
Dec 5, 2025 ·50m
Oct 9, 2025 ·33m
Oct 3, 2025 ·40m
Sep 11, 2025 ·31m
Aug 27, 2025 ·39m
Aug 18, 2025 ·54m